Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 11

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 11
---
 be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting via the internet at https://www.cstproxy.com/cero/2025. However, because you are not the stockholder of record, you may not vote your shares live online at the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent. How can I attend the Annual Meeting? If you are a stockholder of record or a beneficial owner as of the Record Date, you are invited to attend the Annual Meeting live via the internet at https://www.cstproxy.com/cero/2025. You must have your 16 -digitcontrol number listed on the proxy card or in the instructions that accompanied your proxy materials to enter the meeting. The webcast starts at 9:00 a.m. PacificTime. You may vote and submit questions while attending the meeting on the internet. Instructions on how to attend and participate in the Annual Meeting via the internet, including how to demonstrate proof of stock ownership, will be posted at https://www.cstproxy.com/cero/2025. What if I return the proxy card to the Company but do not make specific choices? If you return a signed, dated proxy card to the Company without making any voting selections, the named proxies will vote your shares: • “FOR” Proposal No. 1:The approval of an amendment to our Certificate of Incorporation to combine outstanding shares of our Common Stock into a lesser number of outstanding shares, by a ratio of not less than one -for-twoand not more than one -for-twenty-five, with the exact ratio to be set within this range by our Board in its sole discretion. • “FOR” Proposal No. 2:The approval, subject to certain conditions, of the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635, upon the exercise of February 2025 Common Warrants issued at the February 2025 Registered Direct Offering at less than the “minimum price” under Nasdaq Listing Rule 5635(d), including the issuance of equity compensation to one of the Company’s directors upon the exercise of the February 2025 Common Warrants at less than market value pursuant to Nasdaq Listing Rule 5635(c). • “FOR” Proposal No. 3:The approval, subject to certain conditions, of the issuance